Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Testosterone Followed by Targeted Radioligand Therapy in mCRPC
NCT07476001Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of testosterone cypionate, lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Moffitt Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
testosterone cypionatelutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07476001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476001.